![]() |
Today's News |
Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
Thursday, January 20, 2022Company Profile | Follow Company
Vancouver, BC, January 20, 2022--(T-Net)--Aequus Pharmaceuticals Inc. (TSX-V: AQS,OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced a 1-year extension of terms with Sandoz Canada Inc., with option for parties to renew, for promotional services related to Vistitan (bimatoprost 0.03% ophthalmic solution).
Vistitan eye drops are used to reduce elevated pressure in the eye inpatients with open-angle glaucoma or ocular hypertension.
"The contract extension recognizes a 4-year relationship that has seen Aequus' commercial team consistently grow the Vistitan brand by >30%CAGR over that same period", said Doug Janzen, CEO and Chairman of Aequus.
Grant Larsen, Chief Commercial Officer added, "This extension aligns with our mission to identify complementary and innovative products that provide value to patients and eye care professionals in Canada. We continue to invest in our team and capacity to scale up with additional strategic products and partners in the growing Canadian eye care market."
ABOUT AEQUUS PHARMACEUTICALS INC.
Aequus Pharmaceuticals Inc. (TSX-V: AQS,OTCQB: AQSZF)is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.
Vistitan™: Trademark owned or used under license by Sandoz Canada Inc.
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company's expected revenues; the regulatory approval of its products; the Company's ability to attract international partners; and ongoing discussions with and the Company's ability to secure potential partners to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. [ MORE ] |
Other Recent Company News ![]() |
|||||||||||||||||||
|